Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 22, 2003. The report primarily discloses changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from participation in employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share ownership transactions and does not contain consolidated financial statements or performance metrics for the period.
Material Changes
The filing details specific changes in shareholdings for directors and a retirement fund:
- Mr. J D Coombe: Acquired 3 Ordinary Shares on April 17, 2003, via the Dividend Reinvestment element of the ShareReward Plan at a price of £12.12 per share.
- GlaxoSmithKline US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund decreased from 18,597,880 to 18,566,503 on April 16, 2003, at an average price of $38.84. Dr. J P Garnier is noted as a potential beneficiary of this fund.
- Dr. J P Garnier: Increased his interest by 1,669.627 Ordinary Share ADRs on April 22, 2003, following the reinvestment of dividends paid on April 17, 2003. The transaction price was $38.525 per ADR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, risk factors, contingencies, or unusual items. The content is limited to regulatory disclosures regarding director share ownership.
Key Facts for Investor Verification
- Verify the impact of the ShareReward Plan and dividend reinvestment on director equity compensation.
- Confirm the current share price trends relative to the transaction prices disclosed (£12.12 and ~$38.50-$38.84).
- Review the full annual report (Form 20-F) for comprehensive financial performance data, as this 6-K filing contains no operational or financial results.